https://open.library.emory.edu/concern/publications/16cba88a-90f4-4098-a94d-e2739ecb7485
Asymmetric Binding to NS5A by Daclatasvir (BMS-790052) and Analogs Suggests Two Novel Modes of HCV...
Asymmetric Binding to NS5A by Daclatasvir (BMS-790052) and Analogs Suggests Two Novel Modes of HCV Inhibition
https://adisinsight.springer.com/drugsafety/803519863?error=cookies_not_supported&code=e1beb4cd-03ff-49e8-bbca-811cd0a017bb
Daclatasvir/sofosbuvir - AdisInsight
A Quasi experimental study conducted from January 2019 to June 2019 which included 255 patients described a 39-year-old man*, who experienced lack of efficacy
daclatasvirsofosbuviradisinsight
https://www.fool.com/investing/general/2014/01/15/bristols-daclatasvir-may-prove-a-winner.aspx
Bristol-Myers Squibb Co.'s Daclatasvir May Prove a Winner | The Motley Fool
Jan 15, 2014 - In the crowded market for treating hepatitis C, Bristol-Myers (BMY) may find a willing market for its promising drug daclatasvir.
bristol myers squibb
https://hepatitiscnewdrugs.blogspot.com/2011/11/psi-7977-and-daclatasvir-12-wk.html
PSI-7977 and Daclatasvir (BMS-790052) 12 wk Interferon-Free Tx Arms Added-Genotype 1
https://adisinsight.springer.com/drugsafety/803283897?error=cookies_not_supported&code=fbf64953-9103-4946-bbcb-270594818d1d
Asunaprevir/daclatasvir - AdisInsight
In a single centre retrospective longitudinal observational study, four elderly patients [sexes and specific ages not stated] were described, who developed
daclatasviradisinsight